ホームWXIBF • OTCMKTS
add
WuXi Biologics (Cayman) Inc
市場ニュース
財務情報
損益計算書
収益
純利益
| (CNY) | 2024年6月info | 前年比変化率 |
|---|---|---|
収益 | 42.87億 | 0.97% |
営業費用 | 7.65億 | 21.62% |
純利益 | 7.50億 | -33.86% |
純利益率 | 17.48 | -34.51% |
1 株当たりの収益 | — | — |
EBITDA | 12.36億 | -13.32% |
実効税率 | 11.36% | — |
貸借対照表
総資産
負債総額
| (CNY) | 2024年6月info | 前年比変化率 |
|---|---|---|
現金および短期投資 | 95.29億 | 9.60% |
総資産 | 561.06億 | 7.60% |
負債総額 | 114.65億 | -12.46% |
純資産 | 446.41億 | — |
発行済み株式 | 41.51億 | — |
帳簿価格 | 0.19 | — |
総資産利益率 | 4.05% | — |
資本利益率 | 4.62% | — |
キャッシュ フロー
現金の純増減額
| (CNY) | 2024年6月info | 前年比変化率 |
|---|---|---|
純利益 | 7.50億 | -33.86% |
営業キャッシュ フロー | 6.51億 | -52.65% |
投資キャッシュ フロー | -1.91億 | 75.93% |
財務キャッシュ フロー | -7.38億 | -684.70% |
現金の純増減額 | -2.58億 | -153.79% |
フリー キャッシュ フロー | 3.51億 | 52.56% |
概要
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
設立
2010
ウェブサイト
従業員数
12,435
